The studies diagnosed patients with active lupus and randomized them to receive Benlysta plus standard therapy, or an inactive infused solution (placebo) plus standard therapy.
Worse, however, was the finding that Tredaptive plus statin therapy resulted in a statistically significant increase in non-fatal adverse events observed, such as diabetic complications, new onset diabetes, GI and musculoskeletal effects.
Data from the Women's Health Initiative and other large-scale trials suggest estrogen plus progestin therapy moderately reduces risk for fractures but increases the chance of developing strokes, dementia, deep vein thrombosis, urinary incontinence and gallbladder disease.